Correlation analysis between molecular subtypes and Nottingham Prognostic Index in breast cancer

被引：10
作者：
Zhen, Hongchao [1 ]
Yang, Liuting [2 ]
Li, Li [1 ]
Yu, Junxian [3 ]
Zhao, Lei [1 ]
Li, Yingying [4 ]
Li, Qin [1 ]
机构：
[1] Capital Med Univ, Beijing Friendship Hosp, Dept Oncol, Beijing 100050, Peoples R China
[2] Shanxi Med Univ, Dept Biochem & Mol Biol, Basic Med Coll, Taiyuan 030001, Shanxi, Peoples R China
[3] Capital Med Univ, Beijing Friendship Hosp, Dept Pharm, Beijing 100050, Peoples R China
[4] Capital Med Univ, Dept Pathol & Pathophysiol, Basic Med Coll, Beijing 100069, Peoples R China
来源：
ONCOTARGET | 2017年 / 8卷 / 43期
基金：
中国国家自然科学基金;
关键词：
molecular subtypes; Nottingham Prognostic Index; breast cancer; prognosis; correlation analysis; DECISION-MAKING TOOL; PLUS NPI PLUS; TUMOR SIZE; RECURRENCE; SURVIVAL; WOMEN; CHEMOTHERAPY; RECEPTOR; THERAPY; RISK;
D O I：
10.18632/oncotarget.18242
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Molecular subtypes and Nottingham Prognostic Index (NPI) are both prognostic models for breast cancer patients. We evaluated the association between molecular subtypes and NPI in 1042 breast cancer patients. The molecular subtypes indicating poorer prognosis were positively correlated to higher NPI (r = 0.138, P = 0.001). ER positive expression and PR high expression were positively correlated with NPI (r = 0.142, P = 0.001; r = 0.139, P = 0.001; respectively) and negatively correlated with histological grade (r = -0.233, P < 0.001; r = -0.176, P < 0.001; respectively). Ki67 status was negatively correlated with NPI and positively correlated with histological grade (r = -0.120, P = 0.004; r = 0.197, P < 0.001; respectively). The percentages of cases with NPI score 2.00-3.40 were higher in the luminar A, ER+, PR high expression and Ki67 low expression group, and the percentages of cases with NPI > 5.40 were higher in the HER2 overexpression subtype, basal-like subtype, ER-, PR low/negative expression, and Ki67 high expression groups. The excellent consistence was observed between histological grade and molecular subtypes, ER, PR, Ki67. The difference of histological grade between the HER2 positive and negative group was statistically significant. In conclusion, there was closely association between molecular subtypes and NPI in breast cancer. For further comparing the prognostic significance of molecular subtypes and NPI, survival analyses should be performed on the same population in a large-scale prospective study.
引用
收藏
页码：74096 / 74105
页数：10
相关论文
共 37 条
[1]   Nottingham Prognostic Index in Triple-Negative Breast Cancer: a reliable prognostic tool? [J].
Albergaria, Andre ;
Ricardo, Sara ;
Milanezi, Fernanda ;
Carneiro, Vtor ;
Amendoeira, Isabel ;
Vieira, Daniella ;
Cameselle-Teijeiro, Jorge ;
Schmitt, Fernando .
BMC CANCER, 2011, 11
[2]   Basal-like breast cancer defined by five biomarkers has superior prognostic value then triple-negative phenotype [J].
Cheang, Maggie C. U. ;
Voduc, David ;
Bajdik, Chris ;
Leung, Samuel ;
McKinney, Steven ;
Chia, Stephen K. ;
Perou, Charles M. ;
Nielsen, Torsten O. .
CLINICAL CANCER RESEARCH, 2008, 14 (05) :1368-1376
[3]   Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer? [J].
Chollet, P ;
Amat, S ;
Belembaogo, E ;
Curé, H ;
de Latour, M ;
Dauplat, J ;
Le Bouëdec, G ;
Mouret-Raynier, MA ;
Ferrière, JP ;
Penault-Llorca, F .
BRITISH JOURNAL OF CANCER, 2003, 89 (07) :1185-1191
[4]   THE IMPORTANCE OF HISTOLOGIC GRADE IN LONG-TERM PROGNOSIS OF BREAST-CANCER - A STUDY OF 1,010 PATIENTS, UNIFORMLY TREATED AT THE INSTITUT-GUSTAVE-ROUSSY [J].
CONTESSO, G ;
MOURIESSE, H ;
FRIEDMAN, S ;
GENIN, J ;
SARRAZIN, D ;
ROUESSE, J .
JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (09) :1378-1386
[5]   The molecular profile of luminal B breast cancer [J].
Creighton, Chad J. .
BIOLOGICS-TARGETS & THERAPY, 2012, 6 :289-297
[6]   Pattern of metastatic spread in triple-negative breast cancer [J].
Dent, Rebecca ;
Hanna, Wedad M. ;
Trudeau, Maureen ;
Rawlinson, Ellen ;
Sun, Ping ;
Narod, Steven A. .
BREAST CANCER RESEARCH AND TREATMENT, 2009, 115 (02) :423-428
[7]   Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients [J].
Engstrom, M. J. ;
Opdahl, S. ;
Hagen, A. I. ;
Romundstad, P. R. ;
Akslen, L. A. ;
Haugen, O. A. ;
Vatten, L. J. ;
Bofin, A. M. .
BREAST CANCER RESEARCH AND TREATMENT, 2013, 140 (03) :463-473
[8]   Adjuvant Chemotherapy Use and Health Care Costs After Introduction of Genomic Testing in Breast Cancer [J].
Epstein, Andrew J. ;
Wong, Yu-Ning ;
Mitra, Nandita ;
Vachani, Anil ;
Hin, Sakhena ;
Yang, Lin ;
Smith-McLallen, Aaron ;
Armstrong, Katrina ;
Groeneveld, Peter W. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (36) :4259-+
[9]   Tumour size is the only predictive factor of distant recurrence after pathological complete response to neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancers: A sub-study of EORTC 10994/BIG 1-00 phase III trial [J].
Fei, F. ;
Messina, C. ;
Slaets, L. ;
Chakiba, C. ;
Cameron, D. ;
Bogaerts, J. ;
Bonnefoi, H. .
EUROPEAN JOURNAL OF CANCER, 2015, 51 (03) :301-309
[10]   Size surprise? Tumour size, nodal status, and outcome after breast cancer [J].
Foulkes, W. D. .
CURRENT ONCOLOGY, 2012, 19 (05) :241-243
1234